You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
甘李藥業(603087.SH):GZR102注射液Ⅰ期臨牀試驗完成首例受試者給藥

格隆匯5月16日丨甘李藥業(603087.SH)公佈,本公司自主研發的GZR102注射液正在中國開展Ⅰ期臨牀試驗,於近日成功完成首例受試者給藥。

GZR102注射液是一種基礎胰島素/GLP-1RA固定比例複方周製劑,由胰島素周製劑GZR4和GLP-1RA博凡格魯肽以固定比例組成。作爲每週一次皮下注射製劑,GZR102注射液通過創新配方將兩種藥物成分的協同作用最大化。GLP‑1RA與胰島素聯合治療可彌補T2DM多種病理生理缺陷,在增強降糖效果的同時減少每日胰島素用量,減少低血糖和體重增加等不良反應,有望爲糖尿病患者提供一種有效、安全、簡便的聯合治療優選方案。目前,GZR102的全球開發已進入I期臨牀階段。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account